Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="Neyt, Mattias" or (type exact bookEditor and editor="Neyt, Mattias")

Add to list
- PhD Thesis
Economic evaluation of medical innovations

Mattias Neyt

(2006)
Add to list
- Journal Article
- A4
Cost considerations for monoclonal antibody-targeted therapy in cancer: focus on Trastuzumab

Mattias Neyt

(2006) AMERICAN JOURNAL OF CANCER. 5(1). p.19-26
Add to list
- Journal Article
- A1
The long-term evolution of quality, of life for disease-free breast cancer survivors : a comparative study in Belgium

Mattias Neyt and Johan Albrecht (UGent)

(2006) JOURNAL OF PSYCHOSOCIAL ONCOLOGY. 24(3). p.89-123
Add to list
- Journal Article
- A1
An economic evaluation of Herceptin((R)) in adjuvant setting: The Breast Cancer International Research Group 006 trial

Mattias Neyt, Johan Albrecht (UGent) and Veronique Cocquyt (UGent)

(2006) ANNALS OF ONCOLOGY. 17(3). p.381-390
Add to list
- Miscellaneous
- open access
Bureaucratisation and the growth of health care expenditures in Europe

Johan Albrecht (UGent) , Mattias Neyt and Tom Verbeke (UGent)

(2005) Working Paper Faculteit Economie en Bedrijfskunde. 2005/335.
Add to list
- Journal Article
- A1
Comparing the cost of delayed and immediate autologous breast reconstruction in Belgium

Mattias Neyt, Phillip Blondeel (UGent) , CM MORRISON and Johan Albrecht (UGent)

(2005) BRITISH JOURNAL OF PLASTIC SURGERY. 58(4). p.493-497
Add to list
- Journal Article
- A1
Cost-effectiveness of Herceptin (R): A standard cost model for breast-cancer treatment in a Belgian university hospital

Mattias Neyt, Johan Albrecht (UGent) , Bart Clarysse (UGent) and Veronique Cocquyt (UGent)

(2005) INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE. 21(1). p.132-137

Academic Bibliography

Economic evaluation of medical innovations

Cost considerations for monoclonal antibody-targeted therapy in cancer: focus on Trastuzumab

The long-term evolution of quality, of life for disease-free breast cancer survivors : a comparative study in Belgium

An economic evaluation of Herceptin((R)) in adjuvant setting: The Breast Cancer International Research Group 006 trial

Bureaucratisation and the growth of health care expenditures in Europe

Comparing the cost of delayed and immediate autologous breast reconstruction in Belgium

Cost-effectiveness of Herceptin (R): A standard cost model for breast-cancer treatment in a Belgian university hospital

Contents

Support

Contact